Trial reportJPEN. Journal of parenteral and enteral nutrition2014
Pediatric intestinal failure-associated liver disease is reversed with 6 months of intravenous fish oil.
Trial report in JPEN. Journal of parenteral and enteral nutrition, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00969332 (Omegaven and Parenteral Nutrition Associated Cholestasis), which is not on this map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Omegaven and Parenteral Nutrition Associated Cholestasis
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Lipid emulsions for parenterally fed term and late preterm infants.The Cochrane database of systematic reviews · 2019Pooled it
- ESPEN guideline on clinical nutrition in liver disease.Clinical nutrition (Edinburgh, Scotland) · 2019Guideline
- Improved enteral tolerance following step procedure: systematic literature review and meta-analysis.Pediatric surgery international · 2016Pooled it
- Low-Dose Parenteral Soybean Oil for the Prevention of Parenteral Nutrition-Associated Liver Disease in Neonates With Gastrointestinal Disorders.JPEN. Journal of parenteral and enteral nutrition · 2017Trial
- Pathogenesis and Management of Intestinal Failure-Associated Liver Disease.Seminars in liver disease · 2025Review
- Dietary polyamines promote intestinal adaptation in an experimental model of short bowel syndrome.Scientific reports · 2024Article
- Current Insights Regarding Intestinal Failure-Associated Liver Disease (IFALD): A Narrative Review.Nutrients · 2023Review
- Improvement in Intestinal-Failure-Associated Liver Disease by Using Parenteral Fish Oil as Monotherapy: Case-Based Review of the Literature.Reports (MDPI) · 2023Article
- Outcomes in preterm infants who received a lipid emulsion with fish oil: An observational study.JPEN. Journal of parenteral and enteral nutrition · 2023Observational
- Review
- Intravenous Lipid Emulsions in the Prevention and Treatment of Liver Disease in Intestinal Failure.Nutrients · 2021Review
- Fish Oil Emulsion Reduces Liver Injury and Liver Transplantation in Children with Intestinal Failure-Associated Liver Disease: A Multicenter Integrated Study.The Journal of pediatrics · 2021Article
- Short bowel syndrome in infancy: recent advances and practical management.Frontline gastroenterology · 2021Article
- High Dose Intravenous Fish Oil Reduces Inflammation-A Retrospective Tale from Two Centers.Nutrients · 2020Article
- Altered nutrient status reprograms host inflammation and metabolic health via gut microbiota.The Journal of nutritional biochemistry · 2020Review
- MicroRNA 122 Reflects Liver Injury in Children with Intestinal Failure-Associated Liver Disease Treated with Intravenous Fish Oil.The Journal of nutrition · 2020Observational
- New Insights Into Intestinal Failure-Associated Liver Disease in Children.Hepatology (Baltimore, Md.) · 2020Review
- Review
- Long-Term Outcomes in Children With Intestinal Failure-Associated Liver Disease Treated With 6 Months of Intravenous Fish Oil Followed by Resumption of Intravenous Soybean Oil.JPEN. Journal of parenteral and enteral nutrition · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundStudies have suggested that when intravenous (IV) soybean oil (SO) is replaced with fish oil (FO), direct hyperbilirubinemia is more likely to resolve. The necessary duration of FO has not been established. This study seeks to determine if 24 weeks of FO is an effective and safe therapy for intestinal failure-associated liver disease (IFALD). MATERIALS AND
methodsThis is a clinical trial using patients with IFALD between the ages of 2 weeks and 18 years. SO was replaced with FO (1 g/kg/d) in 10 patients who were receiving most of their calories from parenteral nutrition (PN). Patients were compared with 20 historic controls receiving SO. SO for both groups was prescribed by the primary medical team at variable doses. The primary outcome was time to reversal of cholestasis. Secondary outcomes were death, transplant, and full enteral feeds. Safety measurements included growth, essential fatty acid deficiency, and laboratory markers to assess bleeding risk.
resultsThe Kaplan-Meier method estimated that 75% in the FO group would experience resolution of cholestasis by 17 weeks vs 6% in the SO group (P < .0001). When compared with the SO group, the FO group had decreased serum direct bilirubin concentrations at weeks 8 (P = .03) and 12, 16, 20, and 24 weeks (P < .0001). Although length z score at the end of the study increased in the FO group compared with baseline (P = .03), there were no significant differences in other outcomes.
conclusionsA limited duration of FO appears to be safe and effective in reversing IFALD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.